CD8A and neoplasm: Furthermore, CTLA4+ T cells may produce S100A4, promoting the stemness of TNBC cells [14] Targeting CHI3L1 to restore the tumor-killing activity of CD8+ T cells might be a viable approach for treating TNBC.